Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.
Also called NCT04356742
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 198 participants
- Sponsor
- Registry
-
NCT04356742
-
- Other papers using this trial's data
- Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04356742. Randomized; triple masking; primary purpose treatment. Start 2020-05-26 (actual); primary completion 2022-02-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin 10mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Evogliptin 5mg
- Intervention (Drug)
- Metformin≥1000mg
- Lead sponsor
- Dong-A ST Co., Ltd.
Record details
- Record id
cardio:ct-nct04356742- Content hash
474c6772aa9f0e8f4d836da754760063ff5b05610aa27d6c1a3ffddebf45c2e5